NeuraMatrix Completes RMB 100 Million Series A Funding Round Led by Summit Capital to Advance Invasive Brain-Computer Interface Platform

NeuraMatrix, an invasive brain-computer interface platform company, announced the completion of its RMB 100 million Series A round of financing. The round was led by Huagai Capital, with participation from Prosperity7 Ventures (P7), a diversified venture capital fund under Saudi Aramco, and existing investor Matrix Partners China. After the completion of this round of financing, NeuraMatrix will further invest in chip research and development, mass production, software and hardware development, accelerate scientific research, and the mass production of medical devices.

NeuraMatrix was founded at the end of 2019, but the founding team had been conducting related academic research at the University of Pennsylvania and the Max Planck Institute in Germany since 2010. As a start-up incubated by Tsinghua University, NeuraMatrix's founding team is all from technical backgrounds. The two co-founders are professors from Tsinghua University and the Chinese Academy of Sciences, respectively, specializing in brain-computer interface and biomaterials technology with world-leading expertise. The company’s engineering team comes from fields such as biomaterials, chip design, and software, with Ph.D. holders and Ph.D. candidates accounting for over 70%. The marketing and sales team has extensive experience in the medical device and related industries.

Currently, the system-level chip specifically designed for brain-computer interfaces developed by NeuraMatrix has completed the tape-out process, and mass production of devices equipped with the self-developed chip is expected to be achieved by early next year.